Millipore Sigma Vibrant Logo

SCC118 CWR-R1ca Human Prostate Cancer Cell Line

CWR-R1ca Human Prostate Cancer Cell Line is a valuable cell model for castration-recurrent prostate cancer studies.

CWR-R1ca Human Prostate Cancer Cell Line MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
View Products on Sigmaaldrich.com
SCC118
≥1X10⁶ cells/vial  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information
      Description
      Catalogue NumberSCC118
      DescriptionCWR-R1ca Human Prostate Cancer Cell Line
      OverviewCWR-R1ca is a fibroblast-free cell line derived from the castration-resistant or recurrent CWR-R1 human prostate cancer cell line (1). Removal of fibroblasts from the original parental CWR-R1 cells was accomplished by multiple cycles of short-term trypsinization, cloning and pooling single-cell colonies (1). CWR-R1ca cells express AR-FL, and its splice variant AR-V7, CK-8, CK-18 and c-Met and are highly responsive to androgen for growth (1).

      Key Applications:
      • Androgen Receptor Splice Variant 7 (AR-V7) studies
      • Anti-androgen therapy
      • In vivo tumorigenesis
      Alternate Names
      • Fibroblast-Free CWR-R1 cell line
      Background InformationProstate cancer is a leading cause of male cancer mortality. The androgen receptor (AR) is important for normal development and maintenance of the prostate and is also critical for the survival and progression of prostate cancer. Current treatment of advanced or metastatic prostate cancer relies on androgen deprivation by inhibiting androgen synthesis or anti-androgens that bind to the AR ligand binding domain. The initial response to androgen deprivation therapy is favorable, however, most patients inevitably relapse to a more aggressive, castration-resistant prostate cancer (CRPC), caused by continued transactivation of AR.

      CWR-R1ca was derived from the castration-resistant or recurrent CWR-R1 human prostate cancer cell line (1). The original parental CWR-R1 is a human prostate carcinoma epithelial cell line derived from the recurrent CWR22 human xenograft tumors that were harvested from nude mice 140-160 days after castration and express AR full length (AR-FL), AR-V7 and PSA mRNA and protein (2, 3).

      References:
      1. Shourideh M, DePriest A, Mohler JL, Wilson EM, and Koochekpour S (2016) Characterization of Fibroblast-free CWR-R1ca Castration-Recurrent Prostate Cancer Cell Line. The Prostate 76: 1067-1077.
      2. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung H-J, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, and Pretlow TG (1996) CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Research 56: 3042-3046.
      3. Gregory CW, Johnson RT, Mohler, JL, French FS, and Wilson EM (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61: 2892-2898.
      References
      Product Information
      Quality LevelMQ100
      Applications
      ApplicationCWR-R1ca Human Prostate Cancer Cell Line is a valuable cell model for castration-recurrent prostate cancer studies.
      Application NotesThis product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
      Biological Information
      Cell Line Type
      • Cancer Cells
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assurance• Each vial contains ≥ 1X106 viable cells.
      • Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, B, C and HIV-1 & 2 viruses.
      • Cells are negative for mycoplasma contamination.
      • Each lot of cells are genotyped by STR analysis to verify the unique identity of the cell line.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStore in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
      Packaging Information
      Material Size≥1X10⁶ cells/vial
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      SCC118 04054839207174